Clinical Overview

Hair Loss — Evidence-Based Regrowth

Male pattern hair loss (androgenetic alopecia) affects up to 70% of men over a lifetime, driven by genetic sensitivity of scalp follicles to dihydrotestosterone (DHT). Our pharmacist prescribers offer finasteride, dutasteride and minoxidil — the treatments with the strongest clinical evidence — following NICE CKS Alopecia and BAD guidance, with the same clinical standards as a GP consultation.

70%

Men affected by hair loss in their lifetime

90%

Finasteride halts further hair loss

60%

Visible regrowth with minoxidil at 6 months

3–6 mths

Time to visible results with daily use

NHS

NICE CKS Alopecia (androgenetic) · BAD / Primary Care Dermatology Society · SPS Finasteride, Dutasteride, Minoxidil · MHRA.

Clinical data last updated18 Nov 2026 · 14:33

Your prescriber chooses the right medicine for you

Following GPhC guidance for online pharmacies, you’ll be assessed for your condition — not a specific medicine. A GPhC-registered prescriber reviews your assessment and selects the treatment that is clinically appropriate and safe for you. For high-risk medicines they will independently verify your information and, where required, arrange a two-way consultation before supplying anything.

Rx

Ready to begin your assessment?

Your answers will be reviewed by a GPhC-registered pharmacist prescriber. Results typically within 2 hours.